Ensysce Biosciences Inc (ENSC)
0.5467
-0.01
(-2.13%)
USD |
NASDAQ |
Apr 25, 16:00
0.55
0.00 (0.00%)
After-Hours: 20:00
Ensysce Biosciences Total Liabilities (Quarterly): 3.359M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.359M |
| September 30, 2023 | 2.061M |
| June 30, 2023 | 2.565M |
| March 31, 2023 | 4.067M |
| December 31, 2022 | 9.915M |
| September 30, 2022 | 14.71M |
| Date | Value |
|---|---|
| June 30, 2022 | 8.747M |
| March 31, 2022 | 11.26M |
| December 31, 2021 | 24.58M |
| September 30, 2021 | 10.10M |
| June 30, 2021 | 4.029M |
| December 31, 2020 | 7.010M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
2.061M
Minimum
Sep 2023
24.58M
Maximum
Dec 2021
8.534M
Average
7.878M
Median
Total Liabilities (Quarterly) Benchmarks
| Processa Pharmaceuticals Inc | 0.7975M |
| Omeros Corp | 403.25M |
| Relmada Therapeutics Inc | 12.19M |
| NeuroBo Pharmaceuticals Inc | 6.096M |
| MAIA Biotechnology Inc | 7.089M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.708M |
| Shareholders Equity (Quarterly) | -0.3229M |